Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 12/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469577 | 0.95 | HSD17B3 (0.46) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL23027271 | 0.89 | NOTUM (0.45) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL16204540 | 0.85 | NOTUM (0.48) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL15606230 | 0.85 | HSD17B3 (0.47) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL23695165 | 0.83 | NOTUM (0.38) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL25015342 | 0.82 | NOTUM (0.47) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL24349696 | 0.81 | NOTUM (0.46) | NOTUMHSD17B3 | |
| SCHEMBL14887434 | 0.81 | HSD17B3 (0.50) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL17903051 | 0.81 | SMN1; SMN2 (0.49) | NOTUMHSD17B3SMN1; SMN2KDM4EHTT | |
| SCHEMBL24433197 | 0.80 | LMNA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2017-01-12 | — | — | US | disclosed |
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | NOTUM 1849/4885HSD17B3 4060/4885SMN1; SMN2 4483/4885 |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, SCLY, FCGR2A | NOTUM 870/4885HSD17B3 3106/4885SMN1; SMN2 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.